Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour ipsen pharma - smectite aluminium hydroxide-magnesium carbonate - powder for oral suspension - grams

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ipsen sa-nv - smectite dioctaed 3000 mg; aluminium hydroxide-magnesium carbonate coprecipitate 125 mg - powder for oral suspension - smectite dioctaed 3000 mg; aluminium hydroxide-magnesium carbonate 125 mg - diosmectite

Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour ipsen pharma - smectite aluminium hydroxide-magnesium carbonate - powder for oral suspension

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - diosmectite -

Ireland - English - HPRA (Health Products Regulatory Authority)

beaufour schwabe - smectite aluminium hydroxide magnesium hydroxide - oral suspension - 15.8 millilitre

European Union - English - EMA (European Medicines Agency)

leadiant gmbh - chenodeoxycholic acid - xanthomatosis, cerebrotendinous; metabolism, inborn errors - bile and liver therapy - chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

Kenya - English - Pharmacy and Poisons Board

diosmectite - powder for oral suspension - each sachet contains 3g of diosmectite - diosmectite

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - diosmectite -

Israel - English - Ministry of Health

mbi pharma ltd., israel - chenodeoxycholic acid - hard capsule - chenodeoxycholic acid 250 mg - chenodeoxycholic acid - the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (ctx)) in infants, children and adolescents aged 1 month to 18 years and adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ursodeoxycholic acid 250mg;  ;   - capsule - 250 mg - active: ursodeoxycholic acid 250mg     excipient: capsugel white op colloidal silicon dioxide magnesium stearate maize starch pregelatinised maize starch - ursosan is indicated in the treatment of chronic cholestatic liver diseases, including primary biliary cirrhosis (pbc) and primary sclerosing cholangitis (psc). in primary biliary cirrhosis ursodeoxycholic acid improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, i.e. serum bilirubin less that 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.